Belite Bio (Belite Bio) EV-to-EBIT : -38.45 (As of May. 26, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Belite Bio's Enterprise Value is $1,270.46 Mil. Belite Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-33.05 Mil. Therefore, Belite Bio's EV-to-EBIT for today is -38.45.

The historical rank and industry rank for Belite Bio's EV-to-EBIT or its related term are showing as below:

BLTE' s EV-to-EBIT Range Over the Past 10 Years
Min: -113.74 Med: 0 Max: 0
Current: -38.45

BLTE's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs BLTE: -38.45

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Belite Bio's Enterprise Value for the quarter that ended in Mar. 2024 was $1,143.21 Mil. Belite Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-33.05 Mil. Belite Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2.89%.

Belite Bio EV-to-EBIT Historical Data

The historical data trend for Belite Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio EV-to-EBIT Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-56.16

-39.44

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial							-40.36	-17.05	-28.13	-39.44	-34.60

Competitive Comparison of Belite Bio's EV-to-EBIT

For the Biotechnology subindustry, Belite Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belite Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Belite Bio's EV-to-EBIT falls into.

Belite Bio EV-to-EBIT Calculation

Belite Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1270.461	/	-33.045
	=	-38.45

Belite Bio's current Enterprise Value is $1,270.46 Mil.
Belite Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.05 Mil.

Belite Bio (NAS:BLTE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Belite Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-33.045	/	1143.211128
	=	-2.89 %

Belite Bio's Enterprise Value for the quarter that ended in Mar. 2024 was $1,143.21 Mil.
Belite Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.05 Mil.

Belite Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Belite Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.